Tamsulosin
alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: LY-253352, tamsulosin HCl, tamsulosin hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tamsulosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 15 molecular targets, including ADRA1A, Adra1a and ADRA1D. Recorded indications include Benign prostatic hyperplasia.
- Approval status: ofp (first approved 1997 by the FDA).
- Drug class: alpha-Adrenergic Blocker.
- Mechanism of action: Adrenergic alpha-Antagonists.
- Molecular targets: ADRA1A, Adra1a, ADRA1D and Adra1d (15 listed in DrugCentral).
- Indications: Benign prostatic hyperplasia.
- ATC code: G04CA02 (Alpha-adrenoreceptor antagonists).
- Molecular formula: C20H28N2O5S; molecular weight 408.51 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Benign prostatic hyperplasia
Contraindications (11)
- Breastfeeding (mother)
- Cataract surgery
- Disease of liver
- Dizziness
- High-Grade Prostate Cancer
- Intraoperative floppy iris syndrome
- Oligozoospermia
- Orthostatic hypotension
- Pregnancy, function
- Priapism
- Syncope
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic alpha-Antagonists |
|---|---|
| Established pharmacologic class | alpha-Adrenergic Blocker |
Molecular targets (15)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Alpha-1A adrenergic receptor | ADRA1A | unknown | Ki 10.54 |
| Alpha-1A adrenergic receptor | Adra1a | unknown | Ki 10.52 |
| Alpha-1D adrenergic receptor | ADRA1D | unknown | Ki 10.24 |
| Alpha-1D adrenergic receptor | Adra1d | unknown | Ki 10.15 |
| Alpha-1A adrenergic receptor | ADRA1A | unknown | Ki 9.90 |
| Alpha-1B adrenergic receptor | ADRA1B | unknown | Ki 9.70 |
| D(3) dopamine receptor | DRD3 | unknown | Ki 9.55 |
| Alpha-1B adrenergic receptor | ADRA1B | unknown | Ki 9.21 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 9.10 |
| Alpha-2B adrenergic receptor | Adra2b | unknown | Ki 8.17 |
| Alpha-2C adrenergic receptor | ADRA2C | unknown | Ki 8.10 |
| D(2) dopamine receptor | DRD2 | unknown | Ki 7.89 |
| Alpha-2A adrenergic receptor | ADRA2A | unknown | Ki 7.87 |
| 5-hydroxytryptamine receptor 7 | HTR7 | unknown | Ki 7.08 |
| Serotonin 1 (5-HT1) receptor | Htr1a|Htr1b|Htr1d|Htr1f | unknown | Ki 6.03 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-04-15 | FDA | — | BOEHRINGER INGELHEIM |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G04CA02 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
G04CA52 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
G04CA53 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
G04CA54 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- FDA label: CYP2D6 · Actionable PGx
- HCSC label: CYP2D6 · Informative PGx
- Swissmedic label: CYP2D6, CYP3A4 · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Urinary retention | 726.5 |
| Fall | 671.5 |
| Syncope | 640.9 |
| Maternal exposure during pregnancy | 635.0 |
| Haematuria | 584.1 |
| Alopecia | 577.3 |
| Synovitis | 568.9 |
| Benign prostatic hyperplasia | 559.8 |
| Pemphigus | 535.8 |
| Glossodynia | 484.1 |
| Dizziness | 460.3 |
| Orthostatic hypotension | 441.3 |
Chemical structure
| Molecular formula | C20H28N2O5S |
|---|---|
| Molecular weight | 408.51 g/mol |
| CAS number | 106133-20-4 |
| InChIKey | DRHKJLXJIQTDTD-OAHLLOKOSA-N |
| PubChem CID | 129211 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tamsulosin used for?
DrugCentral lists the following indications for Tamsulosin: Benign prostatic hyperplasia.
How does Tamsulosin work?
Tamsulosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1A, Adra1a, ADRA1D and Adra1d.
When was Tamsulosin first approved?
Tamsulosin was first approved by the FDA in 1997.
What drug class does Tamsulosin belong to?
Tamsulosin is in the alpha-Adrenergic Blocker class.
What is the chemical formula of Tamsulosin?
Tamsulosin has the molecular formula C20H28N2O5S and a molecular weight of 408.51 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2562 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200914 — compound record and bioactivity
- PubChem CID 129211 — chemical identifiers
- DrugBank DB00706 — drug record
- FDA UNII G3P28OML5I — substance identity
- DailyMed: FDA labels for Tamsulosin — current prescribing information (label search)
- UniProt P35348 (ADRA1A) — target protein
- UniProt P25100 (ADRA1D) — target protein
- UniProt P35462 (DRD3) — target protein
- UniProt P35368 (ADRA1B) — target protein
- UniProt P08908 (HTR1A) — target protein
- UniProt P18825 (ADRA2C) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.